The offering was fully priced and closed, so no immediate price dislocation is expected. Monitor upcoming clinical trial readouts and the company's ability to execute on commercialization plans, as the extended runway reduces near-term financing risk.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $31.25entry
- T+1 · 6mo ago 0.00%α −0.54% · $31.25
- T+5 · 6mo ago −7.81%α −7.89% · $28.81
- T+20 · 5mo ago +0.83%α +2.56% · $31.51
- T+60 · 3mo ago +10.24%α +5.86% · $34.45
Price Chart
How similar events traded
Executive Summary
Pharvaris closed an underwritten public offering of 4,455,863 ordinary shares at $29.68 per share, raising approximately $124 million in net proceeds. The funds will support late-stage clinical programs, U.S. commercialization, and working capital, extending the company's cash runway into the first half of 2028.
Key Facts
- Offering of 4,455,863 ordinary shares (including full exercise of underwriter option for 581,199 additional shares) closed on May 11, 2026.
- Public offering price of $29.68 per share; net proceeds expected to be approximately $124 million.
- Proceeds to fund R&D for late-stage clinical programs, U.S. sales and marketing team expansion, and working capital.
- Company reported $247 million in cash as of March 31, 2026; offering extends runway into first half of 2028.
- Underwriters include Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Wells Fargo Securities.
Financial Impact
Approximately $124 million in net proceeds raised, representing ~6.2% dilution on ~72 million pre-offering shares outstanding (estimated).
Risk Factors
- Dilution of approximately 6.2% from the offering may pressure near-term share price.
- Execution risk on late-stage clinical programs and U.S. commercialization.
- Biotech sector volatility could impact stock regardless of fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-216957 |
| Document: d134419dex51.htm | 0001193125-26-216957 |
| Document: d134419d6k.htm | 0001193125-26-216957 |
| Document: 0001193125-26-216957-index-headers.html | 0001193125-26-216957 |
| Document: 0001193125-26-216957-index.html | 0001193125-26-216957 |
| Document: 0001193125-26-216957.txt | 0001193125-26-216957 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers